: The trial established dronedarone as a rhythm-control therapy specifically aimed at reducing clinical complications rather than just maintaining sinus rhythm. 2. Dronedarone (Multaq) Usage Guide
Following the ATHENA results, dronedarone was approved with specific administration and safety protocols. : The only recommended dose is 400 mg twice daily . ATHENA HEART [310]
One tablet should be taken with the and one with the evening meal to ensure proper absorption. Target Population : : The trial established dronedarone as a rhythm-control
: Contraindicated in patients with symptomatic heart failure or recent hospitalization for heart failure (NYHA Class IV or symptomatic Class II-III). : The only recommended dose is 400 mg twice daily
Patients with paroxysmal or persistent AF or AFL who are in sinus rhythm or who will be cardioverted.
It is intended to reduce the risk of hospitalization for AF. 3. Safety and Contraindications
